Emprumapimod

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Emprumapimod (PF-07265803) 是一种具有口服活性、选择性的 p38α MAPK 抑制剂，作用于 RPMI-8226 细胞，直接抑制 LPS 诱导产生的 IL-6 (IC50=100 pM)。Emprumapimod 可用于扩张型心肌病和急性炎性疼痛的研究。

Emprumapimod (PF-07265803) is a potent, orally active and selective inhibitor of p38α MAPK directly inhibits LPS-induced IL-6 production from RPMI-8226 cell (IC50=100 pM). Emprumapimod can be used for the research of dilated cardiomyopathy and acute inflammatory pain.

——

Animal Model:LmnaH222P/H222P mice were Dosage:30 mg/kg Administration:Administered orally by gavage starting when mice were 16 weeks of age and continuing until 20 weeks of age Result:There were significant increases in LVEDD and LVESD as well as a decrease in FS, a parameter directly proportional to the LV ejection fraction.

——

MAPK/ERK Signaling

p38 MAPK

p38 MAPK

——

——

765914-60-1

473.52

C24H29F2N5O3

>98% (HPLC)

In Vitro:?DMSO 中的溶解度 : 100 mg/mL (211.18 mM; 超声助溶 )

C(C(C)C)N1C=2C(=CC(OC3=C(F)C=C(F)C=C3)=C(C(N[C@@H](CCN(C)C)C(N)=O)=O)C2)C=N1

——

(-20℃)

With Ice Pack

≥ 2 years